JP2023500326A5 - - Google Patents
Info
- Publication number
- JP2023500326A5 JP2023500326A5 JP2022525704A JP2022525704A JP2023500326A5 JP 2023500326 A5 JP2023500326 A5 JP 2023500326A5 JP 2022525704 A JP2022525704 A JP 2022525704A JP 2022525704 A JP2022525704 A JP 2022525704A JP 2023500326 A5 JP2023500326 A5 JP 2023500326A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- inhibitor
- administered
- subject
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025009336A JP2025061603A (ja) | 2019-11-04 | 2025-01-22 | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930251P | 2019-11-04 | 2019-11-04 | |
| US62/930,251 | 2019-11-04 | ||
| PCT/US2020/058718 WO2021091904A1 (en) | 2019-11-04 | 2020-11-03 | Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025009336A Division JP2025061603A (ja) | 2019-11-04 | 2025-01-22 | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500326A JP2023500326A (ja) | 2023-01-05 |
| JP2023500326A5 true JP2023500326A5 (cg-RX-API-DMAC7.html) | 2023-11-14 |
| JP7767279B2 JP7767279B2 (ja) | 2025-11-11 |
Family
ID=75848061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525704A Active JP7767279B2 (ja) | 2019-11-04 | 2020-11-03 | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
| JP2025009336A Pending JP2025061603A (ja) | 2019-11-04 | 2025-01-22 | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025009336A Pending JP2025061603A (ja) | 2019-11-04 | 2025-01-22 | 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12391946B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4054594A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7767279B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220130669A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115666588A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020380245A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156376A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292596A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005354A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202133854A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021091904A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024504367A (ja) * | 2021-01-22 | 2024-01-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを治療及び改善するための方法 |
| EP4463151A4 (en) | 2022-01-19 | 2025-10-01 | Univ Northwestern | Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6162709B2 (ja) * | 2011-11-01 | 2017-07-12 | セルジーン コーポレイション | シチジンアナログの経口製剤を使用して癌を治療する方法 |
| KR102242077B1 (ko) * | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| PT3456333T (pt) | 2012-12-07 | 2020-06-01 | Geron Corp | Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica |
| US20150342982A1 (en) * | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
-
2020
- 2020-11-03 JP JP2022525704A patent/JP7767279B2/ja active Active
- 2020-11-03 KR KR1020227018385A patent/KR20220130669A/ko active Pending
- 2020-11-03 WO PCT/US2020/058718 patent/WO2021091904A1/en not_active Ceased
- 2020-11-03 US US17/088,303 patent/US12391946B2/en active Active
- 2020-11-03 AU AU2020380245A patent/AU2020380245A1/en active Pending
- 2020-11-03 MX MX2022005354A patent/MX2022005354A/es unknown
- 2020-11-03 TW TW109138275A patent/TW202133854A/zh unknown
- 2020-11-03 EP EP20884376.3A patent/EP4054594A4/en active Pending
- 2020-11-03 CN CN202080091888.8A patent/CN115666588A/zh active Pending
- 2020-11-03 CA CA3156376A patent/CA3156376A1/en active Pending
-
2022
- 2022-04-28 IL IL292596A patent/IL292596A/en unknown
-
2025
- 2025-01-22 JP JP2025009336A patent/JP2025061603A/ja active Pending
- 2025-07-17 US US19/272,636 patent/US20260078379A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016504307A5 (cg-RX-API-DMAC7.html) | ||
| Bahador et al. | From therapy to experimental model: a hundred years of endotoxin administration to human subjects | |
| Savarese et al. | Prevention of chemotherapy and radiation toxicity with glutamine | |
| Freyer et al. | Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news? | |
| KR20200027548A (ko) | 병용 암 요법 | |
| JP2012521435A5 (cg-RX-API-DMAC7.html) | ||
| JP2018517686A5 (cg-RX-API-DMAC7.html) | ||
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| JP2014144962A5 (cg-RX-API-DMAC7.html) | ||
| JP2009530295A5 (cg-RX-API-DMAC7.html) | ||
| Tewes et al. | Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study | |
| Zhang et al. | Combination chemotherapy with low‐dose cytarabine, homoharringtonine, and granulocyte colony‐stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia | |
| Wei et al. | Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy. | |
| Evans et al. | VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group | |
| Ferreri et al. | Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. | |
| JP6895688B2 (ja) | 血液がんの新規治療法及び新規治療剤 | |
| Lee et al. | Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide | |
| Georgoulias et al. | Docetaxel versus docetaxel/cisplatin in patients with advanced non–small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study | |
| US11957701B2 (en) | Therapy and new therapeutic agent for blood cancer | |
| Anderson et al. | Comparison of radiotherapy alone and radiotherapy with chemotherapy using adriamycin and 5-fluorouracil in bronchogenic carcinoma. | |
| Roncadin et al. | Feasibility of total body irradiation in chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphomas | |
| US20210315898A1 (en) | Combination therapy for treating cancer | |
| WO2021172490A1 (ja) | 組み合わせ医薬、およびピリミジン代謝拮抗剤の耐性化の予防または抑制薬 | |
| Wu et al. | Administration of amifostine in the stage of remission induction can benefit the patients with hematological malignancy in autologous stem cell transplantation: a retrospective study | |
| Holmes et al. | A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer |